Pneumocystis pneumonia (PCP) is a major cause of morbidity and mortality in HIV-infected individuals [1]. Although the use of sulfa drugs, trimethoprim-sulfamethoxazole (TMP-SMX) and dapsone, for prophylaxis has greatly decreased the incidence of PCP, sulfa prophylaxis has also been associated with mutations within the dihydropteroate synthase (DHPS) locus of P. jirovecii [2].
consequences. Since Pneumocystis cannot be cultured, studies of putative sulfa drug resistance have focused on correlating DHPS mutations with clinical variables. Most but not all of these studies have found a signifi cant association between sulfa prophylaxis with either TMP-SMX and/or dapsone and the presence of DHPS mutations [8] . However, whether the effect of TMP-SMX and dapsone on DHPS mutations is similar or different is unknown.
In contrast, studies correlating the presence of DHPS mutations and mortality have had confl icting fi ndings. Nonuniform mortality endpoints may be partially responsible for these confl icting results. Three of nine studies examining the impact of DHPS mutations on death have found a signifi cantly increased risk for death at four weeks [9, 10] or at three months [11] while one study observed an unexpected trend towards decreased mortality at six weeks [12] . Efforts to pool or compare previously collected data have been hampered by the different mortality endpoints used in these prior studies, perhaps explaining why the clinical signifi cance of Pneumocystis mutations remains unclear.
While different defi nitions have been used for sulfa prophylaxis and clinical outcomes, the classifi cation schema of mutant DHPS genotypes has been consistently applied in all studies. To date, all studies have compared mutant DHPS to wild-type DHPS and have defi ned mutant as ' any mutant ' inclusive of both pure mutant and mixed infections, with pure mutant defi ned as a specimen with only one mutant DHPS genotype and mixed infection as a specimen harboring at least two DHPS genotypes, including at least one mutant genotype. However, it is unclear whether the decision to group pure mutant and mixed infections together is consistent with its ' phenotype ' .
To examine whether the variable defi nitions for prophylaxis and mortality endpoints and whether grouping pure mutant and mixed infections together could explain the discrepant results of prior studies, we used a 10-year prospective study of HIV-infected patients admitted to San Francisco General Hospital (SFGH) with PCP. We determined how the risk of DHPS mutations and death changed by applying different defi nitions of prophylaxis, mortality endpoints, and DHPS mutant. With the substantial heterogeneity found in published studies and the resultant inability to pool these data, this large single-center study represents an important opportunity to explore these questions.
Methods

Patients
We enrolled consecutive HIV-infected adults hospitalized with microscopically-confi rmed PCP between May 1997 and February 2008. The study protocol was approved by the Institutional Review Boards at the University of California, San Francisco, the Centers for Disease Control and Prevention (CDC), and the University of North Carolina (UNC). The cohort included 372 episodes from 342 patients, of which 215 episodes were previously reported [13] .
Clinical data and specimens
Data were collected via patient interview and chart abstraction using standardized data collection forms. PCP was microscopically confi rmed using a modifi ed Giemsa stain (Diff-Quik) on respiratory samples obtained from sputum induction or bronchoalveolar lavage (BAL) performed during routine clinical care. Respiratory specimens (1 ml of sputum or BAL) were sent to the CDC (May 1997 to July 2002) or to UNC (August 2002 to February 2008 for genotyping via direct sequencing of amplicons generated via a nested PCR protocol targeting the relevant loci in DHPS, as described previously [14] . For patients with multiple episodes of PCP during the study period, only clinical and laboratory data from the last episode of PCP were included in the analysis.
Defi nition and classifi cation of DHPS mutant
As in prior studies, the wild-type DHPS genotype (GenBank Accession Number: U66279) was defi ned as threonine at position 55 (Thr55) and proline at position 57 (Pro57); a mutant genotype was defi ned as any DNA sequence that differed from the wild-type such that alanine at position 55 (Ala55) and/or serine at position 57 (Ser57) were substituted [2, 15] . We further sub-classifi ed DHPS mutations as ' pure mutants ' if only one mutant genotype was identifi ed (Ala55, Ser57, or Ala55 ϩ Ser57) or ' mixed infections ' if at least two genotypes were identifi ed, including at least one mutant genotype; chromatographs were manually inspected at the loci of interest, and secondary peaks Ͼ 20% of the major peak were scored as mixed [14] . Unlike prior studies, we analyzed pure mutant and mixed infections separately, but similar to prior studies, we also combined pure and mixed infections ( ' any mutant ' ).
Defi nitions of prophylaxis and clinical outcomes
Prior studies combined TMP-SMX or dapsone prophylaxis into ' sulfa/sulfone prophylaxis ' [13] . In this study, we defi ned sulfa prophylaxis as TMP-SMX or dapsone prophylaxis use within 12 weeks preceding PCP diagnosis, irrespective of duration, and examined each chemoprophylaxis regimen separately and combined. We examined death (all-cause and PCP death) at three different endpoints used in prior studies: within four, six and 12 weeks after PCP diagnosis. Investigators blinded to DHPS genotype collected patient vital status and cause of death using
Results
During the 10-year study period, 342 HIV-infected patients with 372 episodes of PCP were enrolled. DHPS genotyping was successful in 325 samples. There were no signifi cant differences in clinical characteristics or outcomes between patients whose specimens could and could not be sequenced. Twenty patients had two or more episodes of PCP during SFGH databases and the National Death Registry. Death was classifi ed as PCP death when the physician recorded PCP as the primary cause of death.
Statistical analysis
First, DHPS mutant groups (any mutant, pure mutant or mixed infections) were analyzed as outcomes with prophylaxis as the predictor. Logistic analysis was used to test mutant vs. wild-type. Generalized logits regression with a multinomial distribution was used to test pure mutant vs. mixed mutant vs. wild-type. PCP prophylaxis was treated fi rst as a binary predictor (any sulfa/sulfone vs. none), then as a 3-category predictor (TMP-SMX vs. dapsone vs. none); adjustment was made for prior PCP as a potential confounding factor. Second, mortality endpoints were analyzed as outcomes with mutant group and prior PCP as predictors. We used Kaplan-Meier survival analysis to estimate the cumulative incidence of survival at four, six, and 12 weeks dating from the fi rst respiratory specimen of the last episode of PCP. We compared the equality of survivor functions with regard to DHPS subtype using the log-rank test. Cox regression was used to calculate hazard of death at different follow-up time-intervals dated from the last episode of PCP, adjusting for initial PCP treatment (sulfa/ sulfone vs. non-sulfa/-sulfone treatment) and CD4 cellcount. Statistical signifi cance was defi ned as P -value Ͻ 0.05. Statistics were performed using SAS 9.2 (SAS Institute Inc., Cary, NC, USA). episodes of PCP were enrolled during the study period. DHPS genotyping was unsuccessful for 47 episodes of PCP and were thus excluded, leaving 325 cases of PCP from 301 patients. Twenty patients experienced two or more episodes of PCP during the study period. Because only the last episode of PCP was included in this analysis, we excluded 24 prior cases of PCP. Therefore, 301 patients with a single episode of PCP during the study period were examined in this study. the study period; as we were interested in examining mortality, we only included the last PCP episode for these patients. Therefore, 301 patients with a single episode of PCP during the study period were included in the analysis (Fig. 1) .
Patient characteristics
Overall, the study population was mostly male (90%) with a mean age of 41 years ( Ϯ 8 years; Table 1 ). Patients in this cohort had advanced HIV disease with a median CD4 cell-count of 29 cells/ μ l (interquartile range [IQR] 13 -64 cells/ μ l) and a mean log viral load of 11.8 copies/ml ( Ϯ 1.6 log copies/ml). Twenty-four percent of patients (71/301) were newly diagnosed with HIV infection during their hospitalization for PCP. A new diagnosis of HIV was signifi cantly associated with DHPS genotype (Fisher P ϭ 0.003), with a signifi cantly greater proportion of patients newly diagnosed with HIV having wild-type DHPS than pure mutant DHPS (36% vs. 17%, generalized logits P ϭ 0.001). There were similar proportions of new HIV diagnosis in patients infected with wild-type DHPS compared to the mixed DHPS infection (36% vs. 29%, generalized logits P ϭ 0.35). When we compared the proportion of new HIV diagnosis by pure and mixed mutant subtype, a signifi cantly greater proportion of patients infected with the mixed subtype were newly diagnosed with HIV compared to patients infected with the pure mutant subtype (29% vs. 17%, generalized logits P ϭ 0.04).
Of note, none of the patients newly diagnosed with HIV reported having used sulfa prophylaxis with either TMP-SMX and/or dapsone prior to PCP diagnosis. There were no other signifi cant differences in patient characteristics or PCP severity with respect to DHPS subtype.
DHPS genotypes
Despite the infrequent utilization of sulfa prophylaxis in our cohort, only 69 patients (23%) possessed the DHPS wild-type as the sole genotype (Table 2 ). Compared to wild-type and mixed DHPS infections, pure mutant infections were the most common DHPS subtype (169/301, 56%), with the double mutant genotype (substitutions in positions 55 and 57) being the most common DHPS genotype (159/301, 53%). Sixty-three specimens (21%) were classifi ed as mixed infections, in which at least two DHPS genotypes were present.
Prophylaxis as a predictor of DHPS mutation
Only 28% (85/301) of patients reported having used sulfa prophylaxis: 48 patients reported having used TMP-SMX, 36 patients reported having used dapsone and one patient Notes: * Adjustments made for prior PCP. † Excluding four patients for whom a prior PCP history was unknown, n ϭ 297. ‡ Excluding one patient who used both TMP-SMX and dapsone within 12 weeks prior to admission, n ϭ 296.
reported having used both TMP-SMX and dapsone prophylaxis during the 12 weeks prior to PCP diagnosis. Of note, the proportion of patients reporting sulfa prophylaxis use showed no signifi cant annual variation during the 10-year study period (Poisson test for trend over time P ϭ 0.78). When we applied the prior defi nition of sulfa prophylaxis (sulfa/sulfone prophylaxis) to the prior defi nition of DHPS mutant (any mutant) and adjusted for prior PCP history, prophylaxis was signifi cantly associated with any mutant (adjusted odds ratio [AOR] ϭ 2.87, P ϭ 0.01; Table 3 ). When we examined TMP-SMX and dapsone prophylaxis separately, dapsone (AOR ϭ 5.83, P ϭ 0.02) but not TMP-SMX (AOR ϭ 1.98, P ϭ 0.13) was signifi cantly associated with any mutant. However, when we compared dapsone to TMP-SMX prophylaxis with respect to the likelihood of infection with any mutant, we found that dapsone was not more likely than TMP-SMX to be associated with any mutant infection (OR ϭ 2.94, P ϭ 0.20). When DHPS mutant subtypes (pure and mixed) were examined separately, prophylaxis, irrespective of the defi nition used, was signifi cantly associated with the pure mutant subtype (all P Ͻ 0.04; Table 3 ). In contrast, prophylaxis, irrespective of the defi nition used, was not associated with mixed infections. Similar to patients reporting prophylaxis use, patients with prior PCP were more likely to be infected with the pure mutant subtype than patients without this history. However, prior PCP was not associated with either mixed infections or infection with any DHPS mutant.
Fig. 2 (A) Survival of HIV-infected patients with
DHPS mutation as a predictor of death
Four-, six-, and 12-week vital status was known for 296, 295 and 293 patients, respectively. There were 24 deaths (20 due to PCP) within four weeks following PCP diagnosis, 32 deaths (23 due to PCP) within six weeks following PCP diagnosis, and 42 deaths (25 due to PCP) within 12 weeks following PCP diagnosis. Death (all-cause and PCPattributed mortality) was examined relative to DHPS mutant status adjusting for initial PCP treatment (sulfa/ sulfone vs. non-sulfa/-sulfone) and CD4 cell-count. Comparing wild-type to any DHPS mutant, the cumulative incidence of four-week (4% vs. 9%, difference Ϫ 5%, 95% CI: Ϫ 31 to ϩ 21%, P ϭ 0.78), six-week (4% vs. 13%, difference Ϫ 9%, 95% CI: Ϫ 34 to ϩ 18%, P ϭ 0.67), and 12-week all-cause mortality (9% vs. 16%, difference Ϫ 7%, 95% CI: Ϫ 32 to ϩ 19%, P ϭ 0.66) was similar to infection with any mutant (Fig. 2A) . Similarly, there was no difference in the cumulative incidence of four-week (3% vs. 8%, difference Ϫ 5%; 95% CI: Ϫ 31 to ϩ 22%, P ϭ 0.80), sixweek (3% vs. 9%, difference -6%; 95% CI: Ϫ 32 to ϩ 21%, P ϭ 0.77), and 12-week PCP-attributed mortality (4% vs. 9%, difference Ϫ 5%; 95% CI: -31 to ϩ 21%, P ϭ 0.77) when we compared wild-type infections to infection with any mutant (Fig. 2C) .
When we examined mortality with respect to DHPS subtype (wild-type vs. pure mutant vs. mixed infection), there was also no difference in cumulative incidence of four-, six-and 12-week all-cause mortality (all P Ͼ 0.61, Fig. 2B ) or PCP-attributed mortality (all P Ͼ 0.75, Fig. 2D ). Additionally, infection with a DHPS mutant genotype (any, pure or mixed) was not associated with a changing hazard for death over time (all P Ͼ 0.06, Table 4 ).
Discussion
Applying different defi nitions of sulfa prophylaxis, mortality endpoints and DHPS mutant to our 10-year cohort, there were three main fi ndings. First, prophylaxis, irrespective of the defi nition used, was signifi cantly associated with pure DHPS mutant infection. Second, prophylaxis, irrespective of the defi nition used, was not associated with mixed DHPS infection. Finally, infection with P. jirovecii containing a DHPS mutant genotype was not associated with increased mortality, irrespective of cause of death or DHPS mutant subtype (pure or mixed) nor was infection with a DHPS mutant (any, pure or mixed) associated with a changing hazard for death over time.
Consistent with most prior studies, we found an increased risk of DHPS mutants among patients reporting sulfa prophylaxis [8, 16] . This association appears driven by the selective pressure of prophylaxis favoring a pure mutant infection rather than the specifi c choice of prophylaxis. Only four studies have found no association with sulfa prophylaxis and DHPS mutant. Interestingly, all four studies may have defi ned sulfa prophylaxis differently from those defi nitions used in this study: two studies did not defi ne prophylaxis duration [17, 18] while two studies defi ned prophylaxis as sulfa use for a minimum of one week in the six months preceding PCP diagnosis [9, 19] . Furthermore, one study observed a higher prevalence of mixed infections relative to pure mutant infections [9] . Combined with our study fi ndings, this suggests that differing defi nitions of prophylaxis as well as differing proportions of pure mutant and mixed infections in earlier cohorts may have contributed to the confl icting associations observed in prior studies. Whether PCP is acquired from an environmental source or from person-to-person transmission, P. jirovecii is a ubiquitous organism and repeated exposure over a lifetime is likely. Therefore, with repeated exposures, an HIV-infected, sulfa-na ï ve patient could harbor multiple Pneumocystis DHPS genotypes. Consistent with this theory, our study found a higher proportion of mixed infections among those patients without prior sulfa-drug exposure. This observation is also consistent with the fi ndings of a large multi-center study by Beard et al ., who reported primary PCP, as well as city of residence, are independent risk factors for mixed mutant infections [20] . Conversely, subsequent sulfa exposure would exert a selective pressure favoring one genotype over another, resulting in infection with a single mutant genotype. Indeed, two studies have found an increasing prevalence of DHPS mutant infection since sulfa prophylaxis was fi rst recommended for PCP prevention for people living with HIV in 1989 [2, 11] .
Whether Pneumocystis DHPS mutant infection is associated with important clinical outcomes has been the subject of an even greater debate as prior attempts to answer this question have yielded confl icting results. Despite our investigation of two mortality outcomes (all-cause and PCP death), three different mortality endpoints (four, six and 12 weeks post-PCP diagnosis), and multiple DHPS classifi cation schema, there were no signifi cant associations between DHPS mutant infection and mortality. Two studies have shown that mutations at the DHPS loci confer only modest sulfa drug resistance [6, 7] ; the fact that most patients infected with Pneumocystis DHPS mutants are successfully treated with high-dose sulfa therapy is consistent with the lack of mortality difference observed in our study. There are however, a few potential reasons why Pneumocystis DHPS mutant infection was not associated with a signifi cant increase in mortality in our study. First, our study had a higher prevalence of mixed DHPS infections (21%) compared to prior studies that have observed an association between DHPS mutant infection and death (prevalence range: 0 -3%) [9 -11] . The higher prevalence of mixed infections observed in our study may have potentially impacted a mortality difference from being observed. Second, the proportion of patients newly diagnosed with HIV was highest among the wild-type subtype. Although several studies have reported DHPS mutant infection to be associated with increased PCP severity [2, 9, 11, 13] , patients unaware of their HIV diagnosis may delay seeking medical care, presenting at a later and more advanced stage of PCP. Therefore, the higher proportion of newly diagnosed HIVinfected patients among those with the wild-type genotype may have infl ated mortality in this group and masked a signifi cant mortality difference between DHPS subtypes. Third, despite this study representing the single-largest cohort of HIV-infected patients with PCP to examine the impact of DHPS mutant infection on death, cumulative mortality was low, potentially limiting our ability to detect a signifi cant difference in mortality. Finally, mortality in HIV-infected persons with PCP is complex and is affected not only by the severity of the disease but also by factors such as the severity of HIV/AIDS, the presence of comorbidities, and development of complications. Standardizing methodological variables (predictors and outcomes) in addition to evaluating individual DHPS subtypes, perhaps even individual genotypes, would allow pooling of existing data-sets from different study sites across different time periods, to more defi nitively address this issue.
Our study had limitations. First, there is no universally accepted nomenclature for DHPS mutants; categorization into pure mutant and mixed subtypes is a new classifi cation without a standard for comparison. Our study fi ndings suggest, however, that pure and mixed subtypes behave differently and should thus be considered separately in future studies. Additionally, the selective effect of sulfa prophylaxis on infection with a pure mutant genotype offers an explanation for the confl icting fi ndings of previous studies. Second, our study did not include all previously-used definitions of prophylaxis and mortality endpoints used in earlier studies; we chose to limit the defi nitions of predictor and outcome to those most commonly used, including those used in studies with confl icting fi ndings. Third, our study lacked post-mortem data which would have provided more accurate assignment of cause of death in the study population and on whether DHPS mutant infection was associated with PCP-attributed mortality. Lastly, as a single-center cohort study, our study fi ndings may not be applicable to other populations. However, because rates of losses to follow-up were low (12-week vital status known for 97.3% of patients) and because rates of losses to follow-up were similar by DHPS subtype (any, pure and mixed), any biases secondary to informative censoring are likely to be small.
In conclusion, the major fi ndings of our study were: (1) prophylaxis, irrespective of the defi nition used, was strongly associated with pure mutant infection; (2) prophylaxis was not predictive of mixed infections; and (3) infection with Pneumocystis DHPS mutant was not associated with increased mortality, irrespective of DHPS mutant subtype, cause of death or mortality endpoint used. Future studies should examine individual prophylaxis regimens with respect to DHPS mutant group and standardize clinical outcomes measured thus allowing subsequent results to be pooled as larger studies are likely needed to address this issue comprehensively. Furthermore, DHPS subtypes, perhaps even individual genotypes, should be examined separately with respect to both predictors and outcomes.
